We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mycelx Technologies Corporation | LSE:MYX | London | Ordinary Share | COM SHS USD0.025 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 1.79% | 57.00 | 54.00 | 60.00 | 57.00 | 56.00 | 56.00 | 21,650 | 09:39:41 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Water Supply | 10.03M | -3.99M | -0.1736 | -3.28 | 13.1M |
TIDMMYX TIDMMYXR
RNS Number : 9635S
MyCelx Technologies Corporation
14 March 2023
14 March 2023
MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)
Closure of Restricted Stock Line
MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, confirms the closure of its restricted line of stock will take effect at 8.00 a.m. on 22 March 2023.
Application has been made to the London Stock Exchange for the transfer of an additional 3,539,273 common shares of $0.25 each ("Common Shares") (the "Additional Shares") from the Company's restricted line of stock with the ticker MYXR (identified under ISIN USU624551235) (the "Restricted Line") to the Company's unrestricted line of stock with the ticker MYX (identified under ISIN US62847T2024) (the "Unrestricted Line").
The Additional Shares are constituted of 3,539,273 Common Shares which have been transferred upon expiry of the restricted period under Regulation S of the US Securities Act of 1933.
Trading in the Company's Restricted Line will cease at 8.00 a.m. on 22 March 2023 and all Common Shares currently trading on the Restricted Line will from then on continue to trade on the Unrestricted Line. Certificated holders will also be issued a replacement share certificate, representing their new holding in unrestricted shares.
The Company's issued share capital consists of 22,983,023 Common Shares with no Common Shares held in treasury. Therefore, the total number of voting rights in the Company is 22,983,023 which may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
From 22 March 2023, all of the 22,983,023 Common Shares will be admitted to trading on the Unrestricted Line.
For further information, please contact:
MYCELX Technologies Corporation Connie Mixon, CEO Tel: +1 888 306 6843 Kim Slayton, CFO Canaccord Genuity Limited (Nomad and Sole Broker) Henry Fitzgerald-O'Connor Tel: +44 20 7523 8000 Gordon Hamilton Celicourt Communications (Financial PR) Mark Antelme Tel: +44 20 8434 2754 Jimmy Lea
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCJIMFTMTIBBTJ
(END) Dow Jones Newswires
March 14, 2023 12:50 ET (16:50 GMT)
1 Year Mycelx Technologies Chart |
1 Month Mycelx Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions